BeyondSpring, Inc.

How big is BeyondSpring, Inc.?

As of Jun 18, BeyondSpring, Inc. has a market capitalization of 137.08 million and reported net sales of 1.02 million with a net profit of -53.34 million over the latest four quarters. Shareholder's funds are at -32.90 million, and total assets are 34.31 million as of Dec 24.

As of Jun 18, BeyondSpring, Inc. has a market capitalization of 137.08 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 1.02 million, while the sum of Net Profit for the same period is -53.34 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -32.90 million and Total Assets at 34.31 million.

What does BeyondSpring, Inc. do?

BeyondSpring, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology cancer therapies, with a market cap of approximately $137.08 million and a net profit of -$3 million as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and has a debt equity ratio of 0.29.

Overview: <BR>BeyondSpring, Inc. is a global clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology cancer therapies, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 137.08 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.29 <BR>Return on Equity: 31.32% <BR>Price to Book: -4.84 <BR><BR>Contact Details: <BR>Address: 28 Liberty St Fl 39, NEW YORK NY: 10005-1451 <BR>Tel: 1 646 5284184 <BR>Website: https://www.beyondspringpharma.com/en/

Should I buy, sell or hold BeyondSpring, Inc.?

Who are in the management team of BeyondSpring, Inc.?

As of March 2022, the management team of BeyondSpring, Inc. includes Dr. Huang Lan (Chairman, CEO, Co-Founder) and Dr. Ramon Mohanlal (Chief Medical Officer, EVP of Research and Development). The Board of Directors also features independent directors such as Mr. Patrick Fabbio and Dr. Daniel Zabrowski.

As of March 2022, the management team of BeyondSpring, Inc. includes the following individuals:<BR><BR>- Dr. Huang Lan, who serves as the Chairman of the Board, Chief Executive Officer, and Co-Founder.<BR>- Dr. Ramon Mohanlal, who is the Chief Medical Officer and Executive Vice President of Research and Development, as well as a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Mr. Patrick Fabbio, Mr. Matthew Kirkby, Dr. Quanqi Song, Dr. Yanbin Xie, and Dr. Daniel Zabrowski.

Is BeyondSpring, Inc. overvalued or undervalued?

As of August 13, 2025, BeyondSpring, Inc. is considered overvalued with negative valuation ratios and a 1-year return of -19.44%, significantly underperforming compared to the S&P 500's gain of 17.14%.

As of 13 August 2025, BeyondSpring, Inc. has moved from a risky valuation grade to one that does not qualify. The company is considered overvalued given its negative valuation ratios, including a Price to Book Value of -2.42, an EV to EBIT of -6.89, and an EV to EBITDA of -7.12. In comparison, peers such as Checkpoint Therapeutics, Inc. have an EV to EBITDA of -5.9896, while Journey Medical Corp. shows a more extreme EV to EBITDA of -25.5082, indicating that BeyondSpring is not only underperforming but also not justifiably valued in its sector.<BR><BR>Recent stock performance further underscores this valuation concern, as BeyondSpring has experienced a 1-year return of -19.44%, compared to the S&P 500's gain of 17.14%. This stark contrast in returns highlights the challenges the company faces in the current market environment.

Is BeyondSpring, Inc. technically bullish or bearish?

As of September 8, 2025, BeyondSpring, Inc. shows a mildly bullish trend despite mixed technical indicators and underperformance compared to the S&P 500, with recent returns of -8.02% and -7.03% over the past week and month, respectively.

As of 8 September 2025, the technical trend for BeyondSpring, Inc. has changed from sideways to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting the overall mildly bullish stance. However, the weekly Bollinger Bands are bearish, and the KST and Dow Theory show mildly bearish trends on a monthly basis. <BR><BR>In terms of performance, BeyondSpring has underperformed the S&P 500 over the past week and month, with returns of -8.02% and -7.03% compared to the S&P 500's gains of 1.05% and 2.33%, respectively. Year-to-date, the stock has a return of 5.52%, significantly lagging behind the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but the mixed indicators suggest caution.